TCIM
NDRM

TIAA CREF Investment Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

TIAA CREF Investment Management’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,437
Closed -$367K – 3124
2017
Q3 		$367K Sell
9,437
-19,883
-68% -$731K ﹤0.01% 2952
2017
Q2 		$877K Buy
29,320
+6,920
+31% +$179K ﹤0.01% 2605
2017
Q1 		$595K Buy
22,400
+2,902
+15% +$71.9K ﹤0.01% 2736
2016
Q4 		$433K Buy
19,498
+10,781
+124% +$202K ﹤0.01% 2895
2016
Q3 		$161 Hold
8,717
– – ﹤0.01% 3067
2016
Q2 		$142K Buy
8,717
+4,041
+86% +$68.1K ﹤0.01% 3120
2016
Q1 		$66K Hold
4,676
– – ﹤0.01% 3049
2015
Q4 		$80K Buy
+4,676
New +$91.1K ﹤0.01% 3116

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

TIAA CREF Investment Management's NDRM Position: Q4 2017 in Review

TIAA CREF Investment Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 9,437 shares — an estimated $367K sold.

TIAA CREF Investment Management first reported a position in NDRM in Q4 2015 and held it in 8 quarters. The position peaked at $877K in Q2 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • TIAA CREF Investment Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 9,437 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $367K.
  • TIAA CREF Investment Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2015 and held it in 8 quarters.
  • TIAA CREF Investment Management's NeuroDerm Ltd. Ordinary Shares position peaked at $877K in Q2 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on TIAA CREF Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.